Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
Brigham and Women's Hospital · NCT06252129
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 160
- US sites recruiting
- 1
- Study start
- July 26, 2024
- Record last updated
- March 5, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Lung cancer patients undergoing upfront surgery, highly benefit from a systematic lymph node dissection in the mediastinum and in the surgical specimens. The latter is performed by the pathologist. Developing a standardized technique to dissect the lobectomy specimen has the potential of maximizing the retrieval of all N1 stations lymph nodes. The investigators believe that the adoption of such technique will improve lung cancer staging and identify a higher number of patients that qualify for adjuvant therapies.
Being studied: Subjects undergoing a lung specimen lymph node dissection; Control group
Conditions: Lung Cancer; Lymph Node Metastasis; Pathologic Processes
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Subjects with a lung nodule or mass who are eligible to undergo a lobectomy.
- Subject without any metastasis present.
- Subjects who have peripheral lung nodule location
- Subjects must be 18 years of age or older.
Exclusion Criteria
- Subjects who received preoperative chemotherapy or radiotherapy.
- Subjects who have a lung nodule located in a central location. Central tumors are defined by those infiltrating the lobar airway.
Recruiting US locations
Brigham and Womens Hospital
Boston, MA 02115
Site contact: Paula Ugalde Figueroa THORACIC SURGEON, MD · 617-794-6491 · pugaldefigueroa@bwh.harvard.edu
Study contacts (from the official record)
- Paula Ugalde Figueroa, M.D. · (617) 732-7696 · pugaldefigueroa@bwh.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+